Mayo Clinic researchers map prostate cancer relapse

By using C-11 choline PET and MRI

05-Oct-2016 - A team of Mayo Clinic researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery. Using C-11 choline PET imaging and multiparametric MRI, researchers found an anatomically diverse pattern of recurrence, which may help optimize treatment of ...

Scientists distinguish molecules most capable of fighting prostate cancer

23-Mar-2016 - Scientists from MIPT (Moscow Institute of Physics and Technology), MSU (Moscow State University), and National University of Science and Technology "MISIS" provided an overview of the most promising compounds which can be used as medications for prostate cancer. A team of researchers from the ...

Collaboration on diagnostic test to improve prostate cancer screening

Thermo Fisher Scientific and Karolinska Institute reduce need for biopsies

11-Nov-2015 - Thermo Fisher Scientific Inc., the world leader in serving science, today announced the results of its collaboration with the Karolinska Institute on a groundbreaking clinical study, called Stockholm 3 (STHLM3), aimed at developing a more effective test for prostate cancer than using the ...

Test developed to detect early-stage diseases with naked eye

Prototype ultra sensitive disease sensor developed

31-Oct-2012 - Scientists have developed a prototype ultra-sensitive sensor that would enable doctors to detect the early stages of diseases and viruses with the naked eye, according to research published in Nature Nanotechnology.The team, from Imperial College London, report that their visual sensor technology ...

Intermittent hormone therapy for prostate cancer inferior to continuous therapy

07-Jun-2012 - An international randomized study finds intermittent androgen-deprivation therapy has some quality-of-life benefits, but overall survival times don’t measure up to those seen with continuous therapy.Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous ...

Alpharadin Significantly Improves Overall Survival for Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases

28-Sep-2011 - Algeta ASA announced results from the phase III ALSYMPCA study with the investigational agent Alpharadin (radium-223 chloride). The study met its primary endpoint by significantly improving survival by 44% [hazard ratio (HR)=0.695; p=0.00185] in patients with castration-resistant ...

Urine test shows prostate cancer risk, U-M study finds

Test for gene fusion can assist in the early detection of prostate cancer

12-Aug-2011 - A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.The test supplements an elevated prostate specific antigen, or PSA, ...

Bavarian Nordic Announces Start of Randomized Phase 2 Study Comparing PROSTVAC and Chemotherapy versus Chemotherapy

02-Mar-2011 - Bavarian Nordic A/S announced the initiation of a new multicenter, randomized Phase 2 study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PROSTVAC®. The study will compare PROSTVAC® followed by docetaxel (chemotherapy) versus docetaxel alone.Patients in the ...

OGT Presents Promising Prostate Cancer Biomarker Panel Results

Company optimistic about pilot data and embarks on rigorous clinical study

30-Sep-2010 - Oxford Gene Technology (OGT has presented potentially highly significant, preliminary data on the development of a panel of biomarkers for the diagnosis of prostate cancer. In the pilot study, a set of biomarkers was identified which can distinguish prostate cancer from control samples with both ...

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939

29-Sep-2010 - S*BIO Pte Ltd announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC). The trial is sponsored by the NCIC Clinical Trials Group and will be conducted at eight clinical sites in Canada. ...